Patents by Inventor Adrianus Cornelis VAN DER GRAAF
Adrianus Cornelis VAN DER GRAAF has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230330060Abstract: The invention relates to certain chromanol, quinone or hydroquinone compounds and derivatives thereof for treatment of heart failure with reduced ejection fraction (HFrEF). Specifically, the present invention relates to chromanol compounds chosen from S-(6-hydroxy-2,5,7,8-tetramethylchroman-2yl)(piperazin-1-yl)methanone and S-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(4-(2-hydroxyethyl)piperazin-1-yl)methanone, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: September 21, 2021Publication date: October 19, 2023Inventors: Robert Henk HENNING, Adrianus Cornelis VAN DER GRAAF, Guido KRENNING, Lucas Moritz WIGGENHAUSER
-
Patent number: 11730741Abstract: The present invention relates to the (S) enantiomeric form of certain 6-chromanol derivatives for use as a medicament. Especially, the present invention relates to the (S) enantiomeric form of a 6-chromanol derivative for use as a medicament wherein said 6-chromanol derivative is chosen from the group consisting of (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone; N-(benzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts or bases thereof and pharmaceutically acceptable salts thereof.Type: GrantFiled: August 23, 2018Date of Patent: August 22, 2023Assignee: SULFATEQ B.V.Inventors: Robert Henk Henning, Gerrit Jan Willem Euverink, Guido Krenning, Adrianus Cornelis Van der Graaf
-
Publication number: 20230202997Abstract: The invention relates to certain chromanol, quinone or hydroquinone compounds and derivatives thereof for treatment of sepsis and sepsis-induced organ dysfunction. Specifically, the present invention relates to chromanol compounds chosen from S-(6-hydroxy-2,5,7,8-tetramethylchroman-2yl)(piperazin-1-yl)methanone and S-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(4-(2-hydroxyethyl)piperazin-1-yl)methanone, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 2, 2021Publication date: June 29, 2023Inventors: Hjalmar Roland BOUMA, Guido Krenning, Robert Henk HENNING, Adrianus Cornelis VAN DER GRAAF
-
Publication number: 20230052152Abstract: The invention relates to certain chromanol, quinone or hydroquinone compounds and derivatives thereof for treatment of Alzheimer's disease and/or for improving memory function and/or reducing plaque load. Specifically, the present invention relates to chromanol compounds chosen from (6-hydroxy-2,5,7,8-tetramethylchroman-2yl)(piperazin-1-5 yl)methanone, ((S)-6-hy-droxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride and S-(6-hydroxy-2,5,7,8-tetramethylchro-man-2-yl)(4-(2-hydroxyethyl)piperazin-1-yl)methanone, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: December 11, 2020Publication date: February 16, 2023Inventors: Robert Henk HENNING, Adrianus Cornelis VAN DER GRAAF, Guido KRENNING, Daniël Henri SWART, Christina Françoise DE VEIJ MESTDAGH, Pieter Cornelis VOGELAAR
-
Publication number: 20210345605Abstract: The present invention relates to a biological pest control agent that combats parasitic larvae, that may inhabit cultivation substrate, through enzymatic digestion of the larvaes interior upon ingestion, preferably using proteases and/or chitinases. The present invention can be used to replace current available pesticides and can be incorporated in pest management for horticulture and agriculture.Type: ApplicationFiled: October 22, 2019Publication date: November 11, 2021Inventor: Adrianus Cornelis VAN DER GRAAF
-
Publication number: 20210227822Abstract: This invention is related to a compound with the structural formula (I) wherein, R1, and R2 are independently selected from the group consisting of C1-C6 alkyl and is preferably methyl, ethyl, propyl or isopropyl; R3 is selected from the group consisting of CH2NHR9, C(?O)YR10, —CH2OHType: ApplicationFiled: April 15, 2021Publication date: July 29, 2021Inventors: Adrianus Cornelis VAN DER GRAAF, Andre HEERES, Johannes Paulus Gerardus SEERDEN
-
Patent number: 11006626Abstract: This invention is related to a compound with the structural formula (I) wherein, R1, and R2 are independently selected from the group consisting of C1-C6 alkyl and is preferably methyl, ethyl, propyl or isopropyl; R3 is selected from the group consisting of CH2NHR9, C(?O)YR10, —CH2OHType: GrantFiled: September 27, 2018Date of Patent: May 18, 2021Assignee: Sulfateq B.V.Inventors: Adrianus Cornelis Van Der Graaf, Andre Heeres, Johannes Paulus Gerardus Seerden
-
Publication number: 20210128523Abstract: The present invention relates to medicaments for use in the prophylaxis or treatment of vasoconstriction related disorders or conditions. Specifically, the present invention relates to (2R) enantiomeric form of a 6-chromanol derivative for use in the prophylactic or treatment of vasoconstriction related disorders or conditions. A preferred 6-chromanol derivative is (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone; N-(benzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: August 23, 2018Publication date: May 6, 2021Inventors: Robert Henk Henning, Gerrit Jan Willem Euverink, Guido Krenning, Adrianus Cornelis Van der Graaf
-
Publication number: 20210024485Abstract: The present invention relates to compounds for prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially to compounds for prophylaxis or treatment of diabetic kidney damage. Specifically, the present invention relates to 6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially diabetic kidney organ damage.Type: ApplicationFiled: June 8, 2020Publication date: January 28, 2021Inventors: Adrianus Cornelis van der GRAAF, Robert Henk HENNING, Leo Edwin DEELMAN, Gerrit Jan Willem EUVERINK
-
Publication number: 20200206235Abstract: The present invention relates to the (S) enantiomeric form of certain 6-chromanol derivatives for use as a medicament. Especially, the present invention relates to the (S) enantiomeric form of a 6-chromanol derivative for use as a medicament wherein said 6-chromanol derivative is chosen from the group consisting of (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone; N-(benzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts or bases thereof and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: August 23, 2018Publication date: July 2, 2020Inventors: Robert Henk Henning, Gerrit Jan Willem Euverink, Guido Krenning, Adrianus Cornelis Van der Graaf
-
Patent number: 10676452Abstract: The present invention relates to compounds for prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially to compounds for prophylaxis or treatment of diabetic kidney damage. Specifically, the present invention relates to 6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially diabetic kidney organ damage.Type: GrantFiled: May 12, 2016Date of Patent: June 9, 2020Assignee: Sulfateq B.V.Inventors: Adrianus Cornelis Van Der Graaf, Robert Henk Henning, Leo Edwin Deelman, Gerrit Jan Willem Euverink
-
Patent number: 10426771Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug deliver devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl) (piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).Type: GrantFiled: January 26, 2018Date of Patent: October 1, 2019Assignee: Sulfateq B.V.Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
-
Patent number: 10322124Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug delivery devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).Type: GrantFiled: January 26, 2018Date of Patent: June 18, 2019Assignee: Sulfateq B.V.Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
-
Publication number: 20190098890Abstract: This invention is related to a compound with the structural formula (I) wherein, R1, and R2 are independently selected from the group consisting of C1-C6 alkyl and is preferably methyl, ethyl, propyl or isopropyl; R3 is selected from the group consisting of CH2NHR9, C(?O)YR10, —CH2OHType: ApplicationFiled: September 27, 2018Publication date: April 4, 2019Inventors: Adrianus Cornelis VAN DER GRAAF, Andre HEERES, Johannes Paulus Gerardus SEERDEN
-
Patent number: 10123529Abstract: This invention is related to a compound with the structural formula (I) wherein, R1, and R2 are independently selected from the group consisting of C1-C6 alkyl and is preferably methyl, ethyl, propyl or isopropyl; R3 is selected from the group consisting of CH2NHR9, C(?O)YR10, —CH2OHType: GrantFiled: December 18, 2013Date of Patent: November 13, 2018Assignee: Sulfateq B.V.Inventors: Adrianus Cornelis Van Der Graaf, Andre Heeres, Johannes Paulus Gerardus Seerden
-
Publication number: 20180280384Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug deliver devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl) (piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: January 26, 2018Publication date: October 4, 2018Applicant: Sulfateq B.V.Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
-
Publication number: 20180250294Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug delivery devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: January 26, 2018Publication date: September 6, 2018Applicant: Sulfateq B.V.Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning
-
Publication number: 20180169220Abstract: The present invention relates to a composition comprising purified natural Der p1 and purified natural Der p2 allergens for use in the treatment of house-dust mite allergy in mammals, like humans. The invention further pertains pharmaceutical compositions for allergy-specific immune therapy. Specifically, the invention discloses reduced responsiveness to subsequent house dust mite allergen exposure after treatment with a pharmaceutical composition comprising purified natural Der p1 and purified natural Der p2 characterized by reduction in Th2 cell activity and reduction in CCL20 release.Type: ApplicationFiled: May 26, 2016Publication date: June 21, 2018Applicant: CITEQ B.V.Inventors: Gerrit Jan Willem EUVERINK, Laura HESSE, Martijn Christiaan NAWIJN, Adrianus Cornelis VAN DER GRAAF
-
Publication number: 20180170892Abstract: The present invention relates to compounds for prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially to compounds for prophylaxis or treatment of diabetic kidney damage. Specifically, the present invention relates to 6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially diabetic kidney organ damage.Type: ApplicationFiled: May 12, 2016Publication date: June 21, 2018Applicant: Sulfateq B.V.Inventors: Adrianus Cornelis VAN DER GRAAF, Robert Henk HENNING, Leo Edwin DEELMAN, Gerrit Jan Willem EUVERINK
-
Patent number: 9913841Abstract: The present invention relates to compounds for the treatment of chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis. The present invention further relates to drug delivery devices suitable to be used in the treatment of chronic obstructive airway diseases such as a nebulizer comprising the present compounds. Specifically, the present invention relates to (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-di-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the treatment of chronic obstructive airway diseases, preferably chronic obstructive pulmonary disease (COPD) or asthma or bronchiectasis, more preferably chronic obstructive pulmonary disease (COPD).Type: GrantFiled: June 17, 2015Date of Patent: March 13, 2018Assignee: Sulfateq B.V.Inventors: Adrianus Cornelis Van der Graaf, Martina Schmidt, Gerrit Jan Willem Euverink, Hermanus Meurs, Robert Henk Henning